-+ 0.00%
-+ 0.00%
-+ 0.00%

Humacyte regains exclusive ex-U.S. Symvess distribution rights from Fresenius Medical Care

PUBT·04/24/2026 12:03:09
Listen to the news
Humacyte regains exclusive ex-U.S. Symvess distribution rights from Fresenius Medical Care
  • Humacyte amended distribution agreement with Fresenius Medical Care to regain exclusive rights to distribute Symvess outside U.S.
  • Fresenius will receive low-single-digit royalties on Humacyte net Symvess sales outside U.S.
  • U.S. Symvess distribution terms under agreement remain unchanged.
  • Rights realignment positions Humacyte to pursue international expansion, including previously announced commercial initiatives in Saudi Arabia, Israel.
  • Change also supports talks with potential partners for international rights, indication-specific rights to Symvess.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.